Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia

Felicia Hernandez, Robert Huether, Lester Carter, Tami Johnston, Jennifer Thompson, James R Gossage, Elizabeth Chao, Aaron M. Elliott

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder caused by mutations in ENG, ACVRL1 and SMAD4, which function in regulating the transforming growth factor beta and bone morphogenetic protein signaling pathways. Symptoms of HHT can be present in individuals who test negative for mutations in these three genes indicating other genes may be involved. In this study, we tested for mutations in two genes, RASA1 and GDF2, which were recently reported to be involved in vascular disorders. To determine whether RASA1 and GDF2 have phenotypic overlap with HHT and should be included in diagnostic testing, we developed a next-generation sequencing assay to detect mutations in 93 unrelated individuals who previously tested negative for mutations in ENG, ACVRL1 and SMAD4, but were clinically suspected to have HHT. Pathogenic mutations in RASA1 were identified in two samples (2.15%) and a variant of unknown significance in GDF2 was detected in one sample. All three individuals experienced epistaxis with dermal lesions described in medical records as telangiectases. These results indicate that the inclusion of RASA1 and GDF2 screening in individuals suspected to have HHT will increase the detection rate and aid clinicians in making an accurate diagnosis.

Original languageEnglish (US)
Article number15040
JournalHuman Genome Variation
Volume2
DOIs
StatePublished - Nov 5 2015

Fingerprint

Hereditary Hemorrhagic Telangiectasia
Genes
Mutation
Bone Morphogenetic Proteins
Transforming Growth Factor beta
Blood Vessels
Assays
Screening
Telangiectasis
Epistaxis
Testing
Medical Records
Skin

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Molecular Biology

Cite this

Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia. / Hernandez, Felicia; Huether, Robert; Carter, Lester; Johnston, Tami; Thompson, Jennifer; Gossage, James R; Chao, Elizabeth; Elliott, Aaron M.

In: Human Genome Variation, Vol. 2, 15040, 05.11.2015.

Research output: Contribution to journalArticle

Hernandez, Felicia ; Huether, Robert ; Carter, Lester ; Johnston, Tami ; Thompson, Jennifer ; Gossage, James R ; Chao, Elizabeth ; Elliott, Aaron M. / Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia. In: Human Genome Variation. 2015 ; Vol. 2.
@article{4c5d1d9c6cd44adf95a9b4601ed891d0,
title = "Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia",
abstract = "Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder caused by mutations in ENG, ACVRL1 and SMAD4, which function in regulating the transforming growth factor beta and bone morphogenetic protein signaling pathways. Symptoms of HHT can be present in individuals who test negative for mutations in these three genes indicating other genes may be involved. In this study, we tested for mutations in two genes, RASA1 and GDF2, which were recently reported to be involved in vascular disorders. To determine whether RASA1 and GDF2 have phenotypic overlap with HHT and should be included in diagnostic testing, we developed a next-generation sequencing assay to detect mutations in 93 unrelated individuals who previously tested negative for mutations in ENG, ACVRL1 and SMAD4, but were clinically suspected to have HHT. Pathogenic mutations in RASA1 were identified in two samples (2.15{\%}) and a variant of unknown significance in GDF2 was detected in one sample. All three individuals experienced epistaxis with dermal lesions described in medical records as telangiectases. These results indicate that the inclusion of RASA1 and GDF2 screening in individuals suspected to have HHT will increase the detection rate and aid clinicians in making an accurate diagnosis.",
author = "Felicia Hernandez and Robert Huether and Lester Carter and Tami Johnston and Jennifer Thompson and Gossage, {James R} and Elizabeth Chao and Elliott, {Aaron M.}",
year = "2015",
month = "11",
day = "5",
doi = "10.1038/hgv.2015.40",
language = "English (US)",
volume = "2",
journal = "Human Genome Variation",
issn = "2054-345X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia

AU - Hernandez, Felicia

AU - Huether, Robert

AU - Carter, Lester

AU - Johnston, Tami

AU - Thompson, Jennifer

AU - Gossage, James R

AU - Chao, Elizabeth

AU - Elliott, Aaron M.

PY - 2015/11/5

Y1 - 2015/11/5

N2 - Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder caused by mutations in ENG, ACVRL1 and SMAD4, which function in regulating the transforming growth factor beta and bone morphogenetic protein signaling pathways. Symptoms of HHT can be present in individuals who test negative for mutations in these three genes indicating other genes may be involved. In this study, we tested for mutations in two genes, RASA1 and GDF2, which were recently reported to be involved in vascular disorders. To determine whether RASA1 and GDF2 have phenotypic overlap with HHT and should be included in diagnostic testing, we developed a next-generation sequencing assay to detect mutations in 93 unrelated individuals who previously tested negative for mutations in ENG, ACVRL1 and SMAD4, but were clinically suspected to have HHT. Pathogenic mutations in RASA1 were identified in two samples (2.15%) and a variant of unknown significance in GDF2 was detected in one sample. All three individuals experienced epistaxis with dermal lesions described in medical records as telangiectases. These results indicate that the inclusion of RASA1 and GDF2 screening in individuals suspected to have HHT will increase the detection rate and aid clinicians in making an accurate diagnosis.

AB - Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder caused by mutations in ENG, ACVRL1 and SMAD4, which function in regulating the transforming growth factor beta and bone morphogenetic protein signaling pathways. Symptoms of HHT can be present in individuals who test negative for mutations in these three genes indicating other genes may be involved. In this study, we tested for mutations in two genes, RASA1 and GDF2, which were recently reported to be involved in vascular disorders. To determine whether RASA1 and GDF2 have phenotypic overlap with HHT and should be included in diagnostic testing, we developed a next-generation sequencing assay to detect mutations in 93 unrelated individuals who previously tested negative for mutations in ENG, ACVRL1 and SMAD4, but were clinically suspected to have HHT. Pathogenic mutations in RASA1 were identified in two samples (2.15%) and a variant of unknown significance in GDF2 was detected in one sample. All three individuals experienced epistaxis with dermal lesions described in medical records as telangiectases. These results indicate that the inclusion of RASA1 and GDF2 screening in individuals suspected to have HHT will increase the detection rate and aid clinicians in making an accurate diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=84983356030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983356030&partnerID=8YFLogxK

U2 - 10.1038/hgv.2015.40

DO - 10.1038/hgv.2015.40

M3 - Article

AN - SCOPUS:84983356030

VL - 2

JO - Human Genome Variation

JF - Human Genome Variation

SN - 2054-345X

M1 - 15040

ER -